Abstract
Vaccination with plasmid DNA expression vectors encoding foreign proteins elicits antibodies and cell-mediated immunity and protects against disease in animal models. We report a comparison of DNA vaccines, using contemporary human strains of virus, and clinically licensed (inactivated virus or subvirion) vaccines in preclinical animal models, to better predict their efficacy in humans. Influenza DNA vaccines elicited antibodies in both non-human primates and ferrets and protected ferrets against challenge with an antigenically distinct epidemic human influenza virus more effectively than the contemporary clinically licensed vaccine. These studies demonstrate that DNA vaccines may be more effective, particularly against different strains of virus, than inactivated virus or subvirion vaccines.
Similar content being viewed by others
Article PDF
References
Ulmer, J.B. et al. Heterologous protective immunity to influenza A by intramuscular injection of DNA encoding a conserved viral protein. Science 259, 1745–1749 (1993).
Montgomery, D.L. et al. Heterologous and homologous protection against influenza A by DNA vaccination: Optimization of DNA vectors. DNA Cell Biol. 12, 777–784 (1993).
Wang, B. et al. Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proc. natn. Acad. Sci. U.S.A. 90, 4156–4160 (1993).
Cox, G.J.M., Zamb, T.J. & Babiuk, L.A. Bovine Herpesvirus 1: Immune responses in mice and cattle injected with plasmid DNA. J. Virol. 67, 5664–5667 (1993).
Xiang, Z.Q. et al. Vaccination with a plasmid carrying the rabies virus glycoprotein gene induces protective immunity against rabies virus. Virology 199, 132–140 (1994).
Both, G.W., Sleigh, M.J., Cox, N.J. & Kendal, A.P. Antigenic drift in influenza virus H3 haemagglutinin from 1968 to 1980: Multiple evolutionary pathways and sequential amino acid changes at key antigenic sites. J. Virol. 48, 52–60 (1983).
Chakraverty, M. et al. Update: Influenza activity-United States and worldwide, and composition of the 1993–94 influenza vaccine. Morbid. Mortal. Weekly Rep. 42, 177–180 (1993).
Shu, L.L., Bean, W.J. & Webster, R.G. Analysis of the evolution and variation of the human influenza A virus nucleoprotein gene from 1933 to 1990. J. Virol. 67, 2723–2729 (1993).
Ito, T. et al. Evolutionary analysis of the influenza A virus M gene with comparison of the Ml and M2 proteins. J. Virol. 65, 5491–5498 (1991).
Rocha, E.P. et al. Comparison of 10 influenza A (H1N1 and H3N2) haemagglutinin sequences obtained directly from clinical specimens to those of MDCK cell- and egg-grown viruses. J. gen. Virol. 74, 2513–2518, (1993).
Nichol, K.L. et al. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. New Engl. J. Med. 331, 778–784 (1994).
Clements, M.L. et al. Use of single-gene reassortant viruses to study the role of avian influenza A virus genes in attenuation of wild-type human influenza A virus for squirrel monkeys and adult human volunteers. J. clin. Microbiol. 30, 655–662 (1992).
Murphy, B.R. et al. Evaluation of three strains of influenza A virus in humans and in owl, cebus, and squirrel monkeys. Infect. Immun. 28, 688–691 (1980).
Berendt, R.F. & Scott, G.H. Evaluation of commercially prepared vaccines for experimentally induced type A/New Jersey/76 influenza virus infections in mice and squirrel monkeys. J. infect. Dis. 136, S712–S717 (1977).
Berendt, R.F. & Hall, W.C. Reaction of squirrel monkeys to intratracheal inoculation with influenza A/New Jersey/76 (swine) virus. Infect. Immun. 16, 476–479 (1977).
Yetter, R.A., Barber, W.H. & Small, P.A. Heterotypic immunity to influenza in ferrets. Infect. Immun. 29, 650–653 (1980).
Smith, H. & Sweet, C. Lessons for human influenza from pathogenicity studies with ferrets. Rev. infect. Dis. 10, 56–75 (1988).
Sears, S.D. et al. Comparison of live, attenuated H1N1 and H3N2 cold-adapted and avian-human influenza A reassortant viruses and inactivated virus vaccine in adults. J. infect. Dis. 158, 1209–1219 (1988).
Couch, R.B. et al. Influenza: Its control in persons and populations. J. Infect. Dis. 153, 431–140 (1986).
Murphy, B.R. et al. Temperature-sensitive mutants of influenza virus. III. Further characterization of the ts-l[E] influenza A recombinant (H3N2) virus in man. J. infect. Dis. 128, 479–487 (1973).
Katz, J.M. & Webster, R.G. Efficacy of inactivated influenza A virus (H3N2) vaccines grown in mammalian cells or embryonated eggs. J. infect. Dis. 160, 191–198 (1989).
Newman, R.S. et al. Immune response of human volunteers and animals to vaccination with egg-grown influenza A (H1N1) virus is influenced by three amino acid substitutions in the haemagglutinin molecule. Vaccine 11, 400–406 (1993).
Sawyer, L.S.W. et al. Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the Cell in which the virus is propagated. J. Virol. 68, 1342–1349 (1994).
Mahr, A. & Payne, L.G. Vaccinia recombinants as vaccine vectors. Immunobiology 184, 126–146 (1992).
Graham, F.L. & Prevec, L. Adenovirus-based expression vectors and recombinant vaccines. Biotechnology 20, 363–390 (1992).
Asano, Y. et al. Experience and reason: 20-year follow-up of protective immunity of the Oka strain live varicella vaccine. Pediatrics 94, 524–526 (1994).
Wolff, J.A. et al. Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle. Hum. molec. Genet. 1, 363–369 (1992).
Manthorpe, M. et al. Gene therapy by intramuscular injection of plasmid DNA: Studies on firefly luciferase gene expression in mice. Hum. Gene Ther. 4, 419–431 (1993).
Clements, M.L. et al. Evaluation of the infectivity, immunogenicity, and efficacy of live cold-adapted influenza B/Ann Arbor/1/86 reassortant virus vaccine in adult volunteers. J. infect. Dis. 161, 869–877 (1990).
Powers, D.C. et al. In elderly persons live attenuated influenza A virus vaccines do not offer an advantage over inactivated virus vaccine in inducing serum or secretory antibodies or local immunologic memory. J. clin. Microbiol. 29, 498–505 (1991).
Yang, Y.P. et al. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc. natn. Acad. Sci. U.S.A. 91, 4407–4411 (1994).
Cooney, E.L. et al. Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet 337, 567–572 (1991).
Redfield, R.R. et al. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. New Engl. J. Med. 316, 673–676 (1987).
Baba, T.W. et al. Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science 267, 1820–1825 (1995).
Kuwano, K. et al. Active immunization against virus infections due to antigenic drift by induction of cross-reactive cytotoxic T lymphocytes. J. exp. Med. 169, 1361–1371 (1989).
Mbawuike, I.N. et al. Influenza A subtype cross-protection after immunization of outbred mice with a purified chimeric NS1/HA2 influenza virus protein. Vaccine 12, 1431–48 (1994).
Fries, L.F. et al. Safety and immunogenicity of a recombinant protein influenza A vaccine in adult human volunteers and protective efficacy against wild-type H1N1 virus challenge. J. infect. Dis. 167, 593–601.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Donnelly, J., Friedman, A., Martinez, D. et al. Preclinical efficacy of a prototype DNA vaccine: Enhanced protection against antigenic drift in influenza virus. Nat Med 1, 583–587 (1995). https://doi.org/10.1038/nm0695-583
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm0695-583
This article is cited by
-
Strategies for Early Vaccination During Novel Influenza Outbreaks
Scientific Reports (2015)
-
Harnessing alveolar macrophages for sustained mucosal T-cell recall confers long-term protection to mice against lethal influenza challenge without clinical disease
Mucosal Immunology (2014)
-
Properties and prospects of adjuvants in influenza vaccination - messy precipitates or blessed opportunities?
Molecular and Cellular Therapies (2013)
-
The Ideal Vaccine: Until Death Do Us Part
Molecular Therapy (2011)